Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Date:10/14/2008

Company's INS-20 Receives Regulatory Clearance to Begin Phase I Clinical Trial

RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical study for the Company's second follow-on biologic (FOB) product candidate, INS-20. Insmed's INS-20 is a pegylated recombinant form of human G-CSF, and an FOB of the FDA-approved product Neulasta(R), which had U.S. sales of approximately $2.4 billion in 2007.

Pre-clinical studies demonstrated that INS-20 and FDA-approved Neulasta(R) are comparable in both their pharmacological and toxicological profile. Detailed analytical characterisation also demonstrated that the products have a high degree of similarity. Data from these initial evaluations have been used, in part, to support the Phase I study, which will be initiated immediately. The Phase I study will be conducted in the United Kingdom and will compare the safety and establish the bioequivalence of INS-20 to Neulasta(R). Results from the trial are anticipated in 2009, and are expected to be used as part of a submission to the FDA to establish a protocol with the agency for a Phase III trial.

"We continue to be pleased by the progress we are making in the development of our FOB portfolio, utilizing our unique protein drug development capabilities and technical expertise," said Dr. Geoffrey Allan, President and CEO of Insmed. "Each development milestone we achieve is further evidence of our strong position as a leader in this evolving industry. We intend to use the data to be generated from the Phase I trial, in combination with the positive pre-clinical results previously garnered, as the basis for discussions with the FDA in an effort to establish a Phase III development path for INS-20."

The initiation of t
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
2. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Delcath ... medical technology company testing its proprietary treatment system ... announced today the signing of its first research, ... Hepatic Perfusion (PHP) System  (the Delcath PHP System™). ... exclusive right to market and sell the Delcath ...
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/8/2010)... Calif. , Feb. 8 PreXion, ... quality 3D Cone Beam Imaging systems for dentistry, today ... as Director of Marketing. ,, PreXion President/COO ... Keith on our senior management team and I look ... extensive sales and marketing leadership, experience and success in ...
Breaking Medicine Technology:Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4PreXion, Inc. Announces Appointment of Director of Marketing 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 1BayCare Named CIO 100 Award Winner by CIO Magazine 47458 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 3NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 1FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 4FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 5FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 6FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 7
... - Research Collaboration to ... Jubilant Organosys Ltd, headquartered in ... Biosys Ltd, has signed a research,collaboration agreement with, ... the international pharmaceutical company,s pre-clinical,pipeline. Under the shared ...
... concludes that new cosmeceutical improves skin barrier function, erythema ... Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, today ... Lotion for Improving the Signs and Symptoms of Rosacea," ...
Other Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
(Date:2/9/2010)... SAINT PAUL, Minn. , Feb. 9 ... death, chronic obstructive pulmonary disease (COPD), is now ... Environmental Public Health Tracking Program. The program focuses ... Minnesota that can be triggered or made ... or outdoor air pollution — asthma, heart attacks ...
(Date:2/9/2010)... for the Heart with ... , Feb. 9 Show your ... gift for the heart with the new ... Recipes Made with Canola Oil" by the American Diabetes ... these recipes for love or give the cookbook as ...
(Date:2/9/2010)... In conjunction with the 2010 Super Bowl, on Feb. ... first-annual Gridiron Greats Night of Champions, a charitable event for ... and Jamie Foxx . Supported by more than ... non-profit organization that provides financial assistance and social services to ... Greats recognized LSI at the event as Medical Partner of ...
(Date:2/9/2010)... (Boston)- Researchers from Boston University,s Slone Epidemiology Center ... status and risk for type 2 diabetes in ... the online American Journal of Epidemiology , ... relationship between neighborhood socioeconomic status and incidence of ... cohort of African-American women. , Type 2 diabetes ...
(Date:2/9/2010)... at the Ireland Cancer Center of University Hospitals (UH) ... lead to a new standard of care for patients ... the February issue of Clinical Cancer Research, ... medicine, Triapine, was well tolerated in combination with standard-of-care ... cancer. This regimen provided both significant reduction in cancer ...
Breaking Medicine News(10 mins):Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2Health News:Neighborhood socioeconomic status and diabetes 2
... Too many obstetricians and hospitals use potentially harmful ... N.Y., Oct. 8 According to Consumer,Reports, many ... result in poor results for newborns and their ... maternity care by taking a quiz,available at CR,s ...
... The Lewin Group released,an independent comparative analysis of ... at the National Press Club in Washington, D.C. The,report ... http://www.lewin.com ., The firm is nationally known ... reform proposals on coverage and costs for the federal,government, ...
... China, Oct. 8 Sinobiomed Inc.,("Sinobiomed", or "the ... that its Board of Directors voted on October ... Company,s Chief Financial Officer under a,Corporate Consulting Services ... In addition, Mr. Choong has been appointed to ...
... LOUIS, Oct. 8 Mass casualty incidents --,such ... calamities,like earthquakes or hurricanes -- raise the life-and-death ... provide treatment for all who,need it. One of ... ventilators for,people requiring respiratory support., Disaster specialists ...
... BUFFALO, N.Y. Cremation, "air burial," grave cairns, funeral ... practices sacred to one culture are often considered "odd" ... were fascinated with the historian Herodotus, description of the ... grill and devouring them in a communal barbeque, something ...
... The National,Community Pharmacists Association (NCPA) is endorsing Sen. ... re-election to the,U.S. Senate. Bruce Roberts, RPh, executive ... statement:, "Senator Norm Coleman is a powerful ... patients they serve. That is why the,National Community ...
Other Medicine News:Health News:CONSUMER REPORTS: Back to Basics For Safer Childbirth 2Health News:CONSUMER REPORTS: Back to Basics For Safer Childbirth 3Health News:CONSUMER REPORTS: Back to Basics For Safer Childbirth 4Health News:CONSUMER REPORTS: Back to Basics For Safer Childbirth 5Health News:CONSUMER REPORTS: Back to Basics For Safer Childbirth 6Health News:The Lewin Group Presents 'McCain and Obama Health Policies: Cost and Coverage Compared' Analysis 2Health News:The Lewin Group Presents 'McCain and Obama Health Policies: Cost and Coverage Compared' Analysis 3Health News:The Lewin Group Presents 'McCain and Obama Health Policies: Cost and Coverage Compared' Analysis 4Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Deathways open doors to unexpected cultural practices 2
... MAGNETOM Trio with Tim™ (Total ... workflow, highest speed, and highest resolution ... up to 16, advanced applications can ... routine. MAGNETOM Trio with Tim is ...
... a set of features for handling business ... that allows staff to customize the system ... Medical Billing's electronic encounter forms, charges can ... care when used with Practice Partner Patient ...
... system is the Cambridge Heart ... (MTWA) testing platform which simplifies ... death risk stratification. This new ... it can be configured to ...
... For those who prefer the versatility that a ... consider the Volk g-2 trabeculum. It features the ... two opposing mirrors angled at 60 and 64 ... NF (no-flange/no-fluid) design. Volk recommends the "Flanged" model ...
Medicine Products: